SBTX vs. ARIX, 4BB, AVCT, CIR, BVXP, TILS, VSN, HVO, MPH, and SCLP
Should you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include Arix Bioscience (ARIX), 4basebio (4BB), Avacta Group (AVCT), Circassia Group (CIR), Bioventix (BVXP), Tiziana Life Sciences (TILS), Verseon (VSN), hVIVO (HVO), Mereo BioPharma Group plc (MPH.L) (MPH), and Scancell (SCLP). These companies are all part of the "biotechnology" industry.
SkinBioTherapeutics vs.
SkinBioTherapeutics (LON:SBTX) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.
In the previous week, SkinBioTherapeutics had 3 more articles in the media than Arix Bioscience. MarketBeat recorded 3 mentions for SkinBioTherapeutics and 0 mentions for Arix Bioscience. Arix Bioscience's average media sentiment score of 0.00 beat SkinBioTherapeutics' score of -0.95 indicating that Arix Bioscience is being referred to more favorably in the news media.
Arix Bioscience has a net margin of 105.64% compared to SkinBioTherapeutics' net margin of -237.95%. Arix Bioscience's return on equity of 6.41% beat SkinBioTherapeutics' return on equity.
Arix Bioscience has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.
16.6% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 20.4% of SkinBioTherapeutics shares are held by insiders. Comparatively, 20.7% of Arix Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Arix Bioscience received 35 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. Likewise, 63.57% of users gave Arix Bioscience an outperform vote while only 60.26% of users gave SkinBioTherapeutics an outperform vote.
SkinBioTherapeutics has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.
Summary
Arix Bioscience beats SkinBioTherapeutics on 12 of the 14 factors compared between the two stocks.
Get SkinBioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SkinBioTherapeutics Competitors List
Related Companies and Tools
This page (LON:SBTX) was last updated on 3/30/2025 by MarketBeat.com Staff
